Nonmuscle myosin II inhibitors for substance use relapse
The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis/marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.
1. A compound or pharmaceutically acceptable salt thereof selected from any of:
2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
5. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
6. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
7. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
8. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
9. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
10. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
11. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
12. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
13. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
14. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
15. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
16. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
17. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
18. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
19. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is: